1. Cell Cycle/DNA Damage
    NF-κB
  2. PPAR

Daidzein (Synonyms: Isoflavone)

Cat. No.: HY-N0019 Purity: 99.69%
Data Sheet SDS Handling Instructions

Daidzein is a soy isoflavone, which acts as a PPAR activator.

For research use only. We do not sell to patients.
Daidzein Chemical Structure

Daidzein Chemical Structure

CAS No. : 486-66-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
500 mg $50 In-stock
1 g $66 In-stock
5 g $120 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Daidzein is a soy isoflavone, which acts as a PPAR activator.

IC50 & Target

PPAR[1]

In Vitro

In 3T3-L1 adipocytes, Daidzein inverses the attenuation of adiponectin gene expression by co-culture, and these effects are inhibited by the PPAR-γ specific inhibitor. Daidzein attenuates the reduction of adiponectin expression in adipocytes, and a PPAR-γ specific inhibitor abrogated this effect. Direct activation of PPAR-α and-γ by Daidzein is confirmed by a luciferase reporter assay. In HEK293T cells, Daidzein significantly increases PPAR-α transcriptional activity in a concentration-dependent manner. Although an obvious dose-dependency is not observed in PPAR-γ transcriptional activity, Daidzein also significantly increases PPAR-γ transcriptional activity over a similar range of concentrations at which Daidzein enhanced PPAR-α transcriptional activity, with a maximum increase at 25 μM[1]. Daidzein is a soy isoflavone, which upregulates the expression of Abcg1, and it promotes axonal outgrowth in cultured hippocampal neurons via estrogen receptor signaling. Daidzein is a major component of soy with structural similarity to estrogen. It exerts an anti-inflammatory effect, lowers lipid levels, and increases mitochondrial biogenesis. As an activator of nuclear receptor peroxisome proliferator-activated receptors (PPARs), Daidzein enhances transcription of PPARs-dependent genes, including liver X receptors (LXRs, Nr1h gene family in mice). Incubation with different concentrations of Daidzein, from 5 to 100 μM, increases APOE transcriptional activity[2].

In Vivo

Treating Apoe KO mice with Daidzein increases Lxr and Abca1 gene expression at 1 month after stroke, showing that the absence of ApoE does not interfere with other cholesterol homeostasis genetic programs. Therefore, the findings suggest that Daidzein-induced ApoE upregulation is a critical component in fostering functional recovery in chronic stroke[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01270737 Chinese University of Hong Kong Hypertension March 2011
NCT00951912 Sun Yat-sen University|Chinese Nutrition Society|Danone Institute International|Department of Health of Guangdong Province Type 2 Diabetes Mellitus August 2009
NCT01556737 Wageningen University Postmenopause November 2011
NCT00596895 University of Florida Biochemical Recurrent Prostate Cancer November 2003 Phase 2
NCT00741208 Northwestern University|Respiratory Health Association of Metropolitan Chicago Asthma August 2008
NCT00204490 The University of Texas Medical Branch, Galveston|National Cancer Institute (NCI)|National Center for Research Resources (NCRR) Breast Cancer April 2004 Phase 2
NCT02007200 National Cancer Institute (NCI) Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Laryngeal Verrucous Carcinoma|Stage I Lip and Oral Cavity Squamous Cell Carcinoma|Stage I Oral Cavity Verrucous Carcinoma|Stag July 2009 Phase 2
NCT02264223 University of Aarhus|Southern Danish University|Herrens Mark A/S|Natur Drogeriet A/S|Future Food Innovation Healthy October 2014
NCT01463436 Trisakti University Cardiovascular Disease|Osteoporosis January 2010 Phase 3
NCT01805674 Rottapharm Spain Menopause March 2013
NCT00043745 Iowa State University|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Osteopenia|Osteoporosis March 2003 Phase 2
NCT01036321 H. Lee Moffitt Cancer Center and Research Institute|National Institute on Minority Health and Health Disparities (NIMHD) Prostate Cancer December 2009 Phase 2
NCT03008785 Federal University of Uberlandia Bloodpressure February 2015 Phase 4
NCT03167827 Federal University of Uberlandia Pelvic Floor September 2016 Phase 4
NCT01232751 Wageningen University Postmenopause August 2010
NCT02373111 Seoul National University Hospital Ageing|Photo-aging March 2015
NCT00905723 Federal University of São Paulo Postmenopausal Symptoms May 2009 Phase 3
NCT00277446 Northwestern University Asthma January 2006
NCT01052116 American Lung Association Asthma Clinical Research Centers|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI) Asthma March 2010 Phase 4
NCT00491595 University of North Carolina|National Cancer Institute (NCI)|University of North Carolina, Chapel Hill Drug Toxicity March 2004 Phase 1
NCT02075112 Emory University|Radiation Therapy Oncology Group Cancer of Head and Neck November 2013 Phase 1
NCT00235924 Laboratoires Arkopharma Postmenopause June 2004 Phase 3
NCT00029796 National Center for Complementary and Integrative Health (NCCIH) Kidney Failure, Chronic Phase 2
NCT00003100 Children's Hospital Medical Center, Cincinnati|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific October 1996
NCT02195609 Instituto Palacios|Ferrer Internacional S.A. Menopause|Hot Flashes March 2014 Phase 4
NCT00262184 National Health Research Institutes, Taiwan|Taiwan Biotech Co., Ltd.|Genovate Biotechnology Co., Ltd., Low Bone Density|Osteopenia December 2004
NCT00042731 H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) Prostate Cancer July 2002
NCT00078923 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Prostate Cancer November 2001 Phase 2
NCT00179556 Beth Israel Deaconess Medical Center|Nichimo - Tokyo, Japan Menopausal Symptoms June 2003 Phase 2|Phase 3
NCT01958372 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer August 2014 Phase 1
NCT00665860 Baylor College of Medicine|University of California|Kaiser Foundation Research Institute|University of Georgia|University of Alabama at Birmingham|Texas A&M University Osteoporosis April 2001
NCT01401946 Brigham and Women's Hospital Hot Flashes May 2000 Phase 4
NCT02806739 University of Massachusetts, Boston|University of Massachusetts, Worcester|Tufts University|Hallmark Health System Gestational Diabetes January 2013 Early Phase 1
NCT00861588 Chinese University of Hong Kong|School of Pharmacy, CUHK Benign Prostate Hyperplasia February 2006
NCT00856882 Chinese University of Hong Kong Diabetes|Cardiovascular Risk October 2007
NCT00668447 United States Department of Agriculture (USDA)|University of Connecticut|National Institute on Aging (NIA) Osteoporosis November 2001 Phase 4
NCT01377961 The University of Texas Medical Branch, Galveston Metabolic Syndrome|Diabetes Mellitus, Non-Insulin-Dependent September 2010
NCT00204425 University of Saskatchewan|Canadian Institutes of Health Research (CIHR) Osteoporosis|Osteopenia December 2004 Phase 3
NCT01553773 Federal University of São Paulo|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Atrophy July 2004 Phase 2
NCT00200824 National Center for Complementary and Integrative Health (NCCIH) Breast Cancer|Prostate Cancer May 2000 Phase 2
NCT00203255 Thomas Jefferson University|Johnson & Johnson Migraine Headache May 2003
NCT00513916 University of Hawaii Cancer Research Center|National Cancer Institute (NCI) Breast Cancer|Healthy, no Evidence of Disease July 2006 Phase 3
NCT02026518 Shahid Beheshti University of Medical Sciences Irritable Bowel Disease January 2014 Phase 4
NCT01219075 University of Southern California|National Cancer Institute (NCI)|California Breast Cancer Research Program BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ductal Breast Carcinoma in Situ|Lobular Breast Carcinoma in Situ|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer July 1, 2010
NCT01116310 Laboratorios Casen-Fleet S.L.U.|Apices Soluciones S.L.|Asociacion Colaboracion Cochrane Iberoamericana Postmenopausal Women With Moderate Vasomotor Symptoms April 2010 Phase 4
NCT01754662 Hull and East Yorkshire Hospitals NHS Trust|University of Hull Type 2 Diabetes|Dietary Intervention October 2011
NCT00301353 TNO|European Commission|National Institute for Research on Food and Nutrition|Institut National de la Recherche Agronomique Osteoporosis October 2002
NCT00925639 Federal University of São Paulo Menopause August 2009 Phase 3
NCT00076050 University of Miami|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Menopause|Osteoporosis|Osteopenia September 2003 Phase 3
NCT00354432 Wake Forest University Health Sciences|National Cancer Institute (NCI) Hot Flashes|Prostate Cancer February 2007 Phase 3
NCT00051402 National Center for Complementary and Integrative Health (NCCIH) Memory Loss|Postmenopause December 2002 Phase 2
NCT01530893 University of East Anglia Cardiovascular Disease Risk Reduction February 2012
NCT00877825 University of Toronto Hyperlipidemia|Cardiovascular Diseases Phase 2
NCT00590538 Children's Hospital of Philadelphia|Cystic Fibrosis Foundation Therapeutics Cystic Fibrosis February 2003 Phase 1|Phase 2
NCT00031720 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Protein Technologies International Breast Cancer|Hot Flashes|Hot Flushes March 2002 Phase 2
NCT00345813 Wake Forest University Health Sciences|National Cancer Institute (NCI) Prostate Cancer October 2003
NCT00016744 Children's Hospital of Philadelphia|Cystic Fibrosis Foundation Therapeutics|National Center for Research Resources (NCRR) Cystic Fibrosis September 2001 Phase 1|Phase 2
NCT00499408 Wake Forest University Health Sciences|National Cancer Institute (NCI) Prostate Cancer April 2007 Phase 2
NCT00343434 Wake Forest University Health Sciences|National Cancer Institute (NCI) Breast Cancer|Obesity January 2005
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 3.9333 mL 19.6665 mL 39.3329 mL
5 mM 0.7867 mL 3.9333 mL 7.8666 mL
10 mM 0.3933 mL 1.9666 mL 3.9333 mL
Cell Assay
[1]

Daidzein is dissolved in DMSO and then diluted with appropriate media[1].

HEK293T cells are plated on 24-well plates at a cell density of approximately 2.5×104 cells/well and are grown to 70-80% confluence. Cells are then transiently transfected with a PPAR-α or PPAR-γ expression plasmid, and a plasmid containing the luciferase gene under the control of three tandem PPAR response elements (PPRE × 3 TK-luciferase) using an X-treme GENE HP DNA Transfection Reagent. Renilla luciferase control vectors are co-transfected to control for transfection efficiency. After transfection, cells are cultured for another 24 h in medium containing DMSO or various concentrations (6.25, 12.5, 25 μM) of Daidzein. Cells are lysed, and luciferase activity is measured and expressed as fold induction, that is normalized to the activity of the renilla luciferase control plasmid[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice[2]
Experiments are performed in 10- to 11-week-old male C57 (C57 bl/6) and Apoe KO (C57 background) mice. For long-term stroke recovery, mice receive Moxifloxacin (100 mg/kg) for 3 d. The prophylactic antibiotic treatment is shown to effectively reduce mortality in an animal model of stroke by attenuating peripheral infection. In addition, saline is subcutaneously administered daily, and hydrogel (Clear H2O) is given to prevent dehydration. With the implementation of poststroke care (antibiotic regimen, rehydration, and feeding hydrogels with soft diet) during the acute period (<1 week), mice start to regain their body weight by day 5 and continue to recover from stroke. Animals are randomly selected for vehicle or Daidzein treatment. Vehicle or Daidzein (10 mg/kg) is administered subcutaneously within 30 min of reperfusion after confirming the reperfusion of blood flow, daily for 7 d and then every other day up to 1 month. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

254.24

Formula

C₁₅H₁₀O₄

CAS No.

486-66-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Daidzein
Cat. No.:
HY-N0019
Quantity: